NONMEM Users Network Archive

Hosted by Cognigen

AstraZeneca -> Clinical Pharmacometrican opportunity

From: Hamrén, Bengt <Bengt.Hamren>
Date: Mon, 3 Apr 2017 11:27:09 +0000

(Senior) Clinical Pharmacometrician

CVMD Quantitative Clinical Pharmacology - Early Clinical Development

Salary: Competitive

Location: Gothenburg, Sweden

Do you have expertise and experience in mathematical modelling and simulati=
on and its application in drug development, plus a pharmaceutical industry =
R&D background? Do you have a good understanding of the concepts of pharma=
cokinetics and drug disposition? If you're a talented and engaged individua=
l, this is an opportunity to join AstraZeneca as a (Senior) Clinical Pharma=
cometrician in Gothenburg supporting projects within the therapy area of Ca=
rdiovascular and Metabolic Disorders
AstraZeneca is a world-leading pharmaceutical company, we focus on discover=
ing and developing medicines that make a real difference to millions of pat=
ients. We are building a state-of-the-art quantitative clinical pharmacolog=
y group with a diverse and uniquely skilled team of pharmacometricians in G=
othenburg, where two of our key therapeutic areas are located. You'll thriv=
e in an environment that inspires innovation, encourages multidisciplinary =
team-working and collaboration with academia, and rewards original scientif=
ic thinking.

Main duties and responsibilities
Working closely with clinical pharmacology scientists, physicians and other=
 scientists, you'll apply modelling to support the design and interpretatio=
n of clinical studies and influence key decisions in early and late clinica=
l development.
The work includes integration of relevant data, such as dose information, p=
harmacokinetics, biomarkers and clinical endpoints within and across studie=
s, compounds and development stages. Support to informative trial designs u=
sing simulations and efficient modeling statistics is an important focus ar=
ea for us. An area to grow is quantitative systems pharmacology and mechani=
stic modelling approaches for more informative translation of disease and d=
rug knowledge. In collaboration with clinical pharmacology scientists, you'=
ll represent Quantitative Clinical Pharmacology and be responsible for iden=
tifying and executing modelling to support model based drug development. Yo=
u will communicate your findings to other scientists within and outside of =
AstraZeneca and publish them in peer reviewed journals.

Essential requirements
You must have:

PhD degree preferred or equivalent relevant experience in quant=
itative science
Strong quantitative modelling skills, e.g. expert knowledge in =
mathematics, statistics, mechanistic systems pharmacology modelling, quanti=
tative translational scaling, model-based meta-analyses

Background and a comprehensive understanding of clinical pharma=
cology aspects of drug development

Experience in pharmaceutical R&D

Working knowledge of pharmacokinetics and its clinical applicat=

Biological understanding of disease and drug action

Excellent oral and written communication skills.

You'll need real passion for your subject, along with a high level of integ=
rity, plus the ability to work in a multi-disciplinary setting that compris=
es a number of specialists in their fields, including physicians, scientist=
s and statisticians.

Desirable requirements
You will ideally have:

Recognised scientific expertise demonstrated by scientific publ=
ishing in the field of clinical pharmacology

Early or late phase clinical development experience/awareness.

More information
For more information about the position please contact: Bengt Hamrn at =
+46 31 7762201
Welcome with your application no later than April 30, 2017.

Bengt Hamrn, PhD
Quantitative Clinical Pharmacology Lead CVMD
AstraZeneca R&D Mlndal
Research and Development | Quantitative Clinical Pharmacology
SE 431 83 Mlndal, Sweden
T: +46 (0)31 776 22 01
Mobile: + 46 (0) 768-774811
e-mail: bengt.hamren

Please consider the environment before printing this e-mail


Confidentiality Notice: This message is private and may contain confidentia=
l and proprietary information. If you have received this message in error, =
please notify us and remove it from your system and note that you must not =
copy, distribute or take any action in reliance on it. Any unauthorized use=
 or disclosure of the contents of this message is not permitted and may be =

Received on Mon Apr 03 2017 - 07:27:09 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: